These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15681435)

  • 1. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
    Pfeiffer JK; Kirkegaard K
    J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
    Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
    Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
    Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
    Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.
    Panigrahi R; Hazari S; Chandra S; Chandra PK; Datta S; Kurt R; Cameron CE; Huang Z; Zhang H; Garry RF; Balart LA; Dash S
    PLoS One; 2013; 8(8):e72791. PubMed ID: 24009705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
    Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
    Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
    Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
    Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
    Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.
    Hmwe SS; Aizaki H; Date T; Murakami K; Ishii K; Miyamura T; Koike K; Wakita T; Suzuki T
    Antiviral Res; 2010 Mar; 85(3):520-4. PubMed ID: 20043953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.
    Satoh S; Mori K; Ueda Y; Sejima H; Dansako H; Ikeda M; Kato N
    PLoS One; 2015; 10(2):e0118313. PubMed ID: 25699517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
    Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
    J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
    Zhou S; Liu R; Baroudy BM; Malcolm BA; Reyes GR
    Virology; 2003 Jun; 310(2):333-42. PubMed ID: 12781720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Benfield T; Bukh J
    J Gen Virol; 2018 Aug; 99(8):1066-1077. PubMed ID: 29927371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
    Delang L; Scheers E; Grabner M; Verpaalen B; Helsen N; Vanstreels E; Daelemans D; Verfaillie C; Neyts J
    Biochem Pharmacol; 2015 Aug; 96(3):190-201. PubMed ID: 26070251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.